Theoretically, COVID-19 patients with DM have a prolonged prothrombin time value, as well as the results in the case-control study design sub-group as seen inFigure 3 which shows a difference, namely a prolonged prothrombin time value in the DM group. The gene discussed is F2; the disease is COVID-19.